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While the life expectancy of the population has increased, Alzheimer’s disease (AD) has emerged as 
one of the greatest health problems of old age. AD is characterized by neuronal loss and cognitive 
decline. In the AD brain, there is a decrease in levels of acetylcholinesterase (AChe) and an increase in 
the levels of the related enzyme butyrylcholinesterase (BChe), that accumulate in plaques and tangles. 
Apolipoprotein e (Apoe) is a major cholesterol carrier and plays an important role in maintaining 
lipid homeostasis. APOE-ε4 constitutes the most important known genetic risk factor for late-onset 
AD. It has been proposed that the BCHE-K allele (Ala539Thr) acts in synergy with the APOE-ε4 
allele to promote risk for AD. However, there is insufficient evidence to support a correlation. Most 
studies focused only on the coding regions of the genes. In this study, we analyzed sequence regions 
beyond the BCHE coding sequence. We found synergy between APOE-ε4 and SNPs localized in 5′UtR 
(rs1126680) and in intron 2 (rs55781031) of the BCHE-K allele (rs1803274) in 18% of patients with 
late-onset AD (n = 55). The results show that the coexistence of the APOE-ε4 allele and 3 SNPs in the 
BCHE gene is associated with a highly elevated risk of late-onset AD. SNP (rs1126680) in 5′UtR of the 
BCHE gene is located 32 nucleotides upstream of the 28 amino acid signal peptide. Mass spectrometry 
analysis of the BChE protein produced by SNP (rs1126680) showed that the mutation caused an in 
frame N-terminal extension of 41 amino acids of the BChE signal peptide. The resultant variant with a 
69 amino acid signal peptide, designated N-BChE, may play a role in development of AD.
Alzheimer’s disease (AD), a neurodegenerative disease associated with cognitive decline is the most common 
form of dementia in elderly individuals. Approximately 13% of people over the age of 65 and 45% over the age of 
85 are estimated to have AD. An estimated 50 million people worldwide lived with dementia in 2017. This num-
ber will almost double every 20 years, reaching 131.5 million in 20501. There are several types of human demen-
tia of which AD is the most common2. Differentiation between AD and dementia with Lewy bodies, vascular 
dementia (VaD) and frontotemporal dementia (FTD) can be challenging at present and ambiguous. Diagnosis 
of AD requires a clinical syndrome of dementia, confirmed by postmortem brain autopsy by detecting cerebral 
pathology including β-amyloid (Aβ) plaques and tau neurofibrillary tangles (NFTs)3,4. However, the presence of 
Aβ in cognitively normal older individuals indicates that other markers are desirable to facilitate more accurate 
diagnosis of AD5–10.
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Alzheimer’s disease (AD) is divided into 2 subtypes: early-onset AD occurring at age 30 to 65 years, with 
approximately 1% to 6% of all cases and late-onset AD, which is the most common form of AD at age later than 65. 
The cause for most Alzheimer’s cases is still unknown except for a few percent of cases where mutations in genes 
APP, PSEN1, and PSEN2 are associated with early-onset AD. Multiple genetic and environmental risk factors are 
involved in late-onset AD pathogenesis11,12. Many studies have shown that an imbalance between the production 
and clearance of amyloid-β (Aβ) forming amyloid plaques, is probably a major contributor to neurodegeneration 
and disease development. The toxicity of Aβ seems to depend on the presence of microtubule-associated hyper-
phosphorylated forms of the protein tau, which aggregate and deposit in AD brains as neurofibrillary tangles13. 
On the other hand, other factors can also be involved in AD development.
The results from genome-wide association studies (GWAS) have shown that the presence of the ε4 allele of 
APOE is the strongest genetic risk factor for AD14–16. Apolipoprotein E (ApoE) is a protein involved in lipid 
transport between cells and tissues and it seems to play a role in Aβ aggregation and clearance. The human APOE 
gene exists in three allelic forms (APOE-ε2, APOE-ε3, and APOE-ε4) which differ only by two amino acids in 
positions 112 and 158, encoding either cysteine or arginine: ApoE2 (Cys112, Cys158), ApoE3 (Cys112, Arg158), 
and ApoE4 (Arg112, Arg158). Individuals carrying the APOE-ε4 allele are at increased risk of AD compared 
with those carrying the more common ε3 or/and ε2 alleles. It has been hypothesized that ApoE2 and ApoE3 
may enhance the clearance of Aβ more efficiently, compared to ApoE4, and/or ApoE4 promotes Aβ fibrillization 
more effectively than ApoE2 and ApoE317–20. Previous studies showed genes expression changes associated with 
lipid metabolism as well as inflammation and a role of ApoE4 in these processes among AD patients21,22. Other 
mechanisms, such as tau phosphorylation, neuroinflammation and a role of BCHE protein in the formation of 
plaques have been also considered as risk factors for AD. Accumulation of amyloid plaques, is thought to initiate 
a pathogenic cascade that leads to synaptic dysfunction and neurodegeneration10.
Butyrylcholinesterase (Uniprot P06276), also known as plasma cholinesterase or pseudocholinesterase, is a 
serine hydrolase present in most tissues with the highest levels in plasma and liver23,24. BChE has a widespread 
distribution in the human body and it serves as an inherent protector from damages caused by toxic compounds 
before they reach acetylcholinesterase (AChE) in synapses. In the brain BChE is found in glia and white matter, 
and it has been shown to be involved, along with AChE, in cholinergic neurotransmission25,26. In the human 
brain, BChE is mainly expressed in glial cells, particularly astrocytes in contrast to AChE which is found in neu-
rons. Nevertheless, BChE is also found in specific populations of neurons, particularly localized in the amygdala 
and hippocampus27 and thalamus25,28. BChE was found in amyloid plaques and neurofibrillary tangles (NFTs), 
which suggests that the protein may be involved in pathogenesis of AD29–31. Other researchers demonstrated 
that BChE may participate in the transformation of beta-amyloid (Aβ) from an initially benign to an eventually 
malignant form32. The accumulation of BChE in cortical grey matter in association with AD pathology, an area 
that normally has scant BChE activity, suggests an opportunity to detect this pathology during life by imag-
ing BChE33,34. Other findings showed that the most frequent genetic variant of the BCHE gene – the K-variant 
(c.1699G> A, p.Ala539Thr, rs1803274), was considerably less effective in attenuating the accumulation of Aβ 
fibrils than BChE wild type35,36. The association between the BChE-K variant and AD risk in patients carrying 
the ApoE4 allele has been debated and studied many times, but no definitive correlation has been established, 
as some support the idea37–39, while other researchers remain doubtful40–42. Despite the fact that many of these 
studies are based on meta-analysis, GWAS and cohort study, the results are inconsistent and a role for BChE in 
AD pathology remains unclear43,44.
Nearly all previous reports regarding BChE involvement in the development of AD focused only on the 
K-variant alteration located in the tetramerization domain of BChE.
Our study shows that mutations in the 5′UTR and intron 2 of the BCHE gene increase the probability of an 
association of the BChE-K variant and APOE-ε4 allele with late-onset AD.
Results
Previous studies reported an association between the K variant (BCHE-K) and late-onset AD risk in carriers 
of APOE-ε4. We attempted to replicate this finding in 55 confirmed AD and 18 age matched controls, while 
expanding the analysis to include noncoding regions of the BCHE gene. Genotype and allele frequencies of the 
BCHE and APOE-ε4 variants analyzed are summarized in Table 1. We found a subpopulation of 10 subjects 
with compound alterations in BCHE (rs1126680, rs55781031, rs1803274) and APOE-ε4 alleles among 55 people 
with late-onset AD. The rs1803274 and APOE-ε4 alleles were found in 8 out of 45 AD patients and in 6 out of 18 
controls. The mutations were mainly heterozygous so that only one allele carried a mutation and the other allele 
was wild-type.
Alterations in noncoding regions of a gene can play various roles in protein synthesis. 5′ UTR modifications 
can change the protein translation start site and modifications in introns can be involved in splicing regula-
tion and gene expression pattern. To determine whether rs1126680 and rs55781031 (c.−32G> A and c.1518-
121 T > C) affected the protein sequence of serum BChE, we isolated BChE from homozygous individuals from 
our serum collection45 by affinity chromatography on Hupresin and size exclusion chromatography. Isolated pro-
teins were analyzed by mass spectrometry of trypsin-digested proteins. Peptides were found that corresponded to 
a new translational start site of BChE (Fig. 1A,B, Supplementary Fig. S2) located −69 amino acids from Glu1 of 
the mature, secreted BChE protein. Furthermore, the extended 69-residue signal peptide was not clipped off the 
secreted BChE protein. To predict the rs1126680 effect on local RNA secondary structure of the first 200 nucle-
otides of the BChE transcript MFOLD algorithm and RNAsnp Web Server were used46–48. We did not observe 
significant changes in the predicted secondary structures outside of the region containing the alteration (Fig. 1C).
Sequence analysis using the Kozak sequence prediction algorithm showed that the new translation start site 
at residue −69 (nucleotide −123 in Table 2) scored higher for the Kozak consensus sequence than the start site 
at residue −28 in wild-type BChE (nucleotide + 1 in Table 2). A perfect Kozak sequence would have a score of 
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1. Scores of 0.17 and 0.14 for the 2 ATG start sites in Table 2 indicate that BChE expression levels are modulated 
through inefficient start site sequences. The slightly higher score of 0.17 suggests the homozygous mutant would 
have higher plasma BChE activity. Contrary to expectation, plasma samples with 3 BCHE SNPs had a lower 
BChE activity. The N-terminus extended BChE protein variant, designated N-BChE, is 41 aa longer than wt and 
carries a substitution at nucleotide −32 position TGC > TAC (c.−32G > A) p.C-11Y (rs1126680) (Fig. 1).
APOE4 (rs7412-C 
and rs429358-C)
Signal peptide 
(rs1126680)
Intron 2 
(rs55781031)
K-variant 
(rs1803274) AD control
+(1 hom, 9 htz) +(1 hom, 9 htz) +(1 hom, 9 htz) +(2 hom, 8 htz) 10 —
+(2 hom, 7 htz) — — +(1 hom, 7 htz) 8 —
+(9 hom, 27 htz) — — — 37 —
+(6 htz) — — +(6 htz) — 6
+(12 htz) — — — — 12
Table 1. Distribution of APOE-ε4 and BCHE alleles in AD patients and elderly controls (EC). All 55 late-
onset AD patients had APOE-ε4. Ten out of 55 late-onset AD patients had 3 BCHE alterations (rs1126680, 
rs55781031, rs1803274) and APOE-ε4. An additional 8 AD patients had the K-variant mutation and APOE-ε4. 
All 18 elderly controls had APOE-ε4. None of the controls had 3 BChE mutations, though 6 out of 12 controls 
had the K-variant mutation and APOE-ε4. SNP rs1126680 is located 32 nucleotides upstream from the ATG 
start site at codon −28 (initiation codon of the wt BChE- No. 3 in Fig. 1), earlier described as the −116A 
variant. Full table in Supplementary Table S1. The letter C in APOE4 rs429358-C represents mutation of 
TGC (Cys) to CGC (Arg) at residue 112 (130 including the signal peptide) in UniProt accession P02649, 
and the presence of CGC (Arg) at residue 158 (176) in rs7412. Hom stands for homozygous, htz stands for 
heterozygous.
Figure 1. 5′ sequence of BCHE gene. (A) The cDNA and corresponding amino acid sequence of N-terminal 
part of BChE. Predicted translation initiation codons ATG in the first 200 nt of the BCHE cDNA are shown as 
enlarged bold letters. The proposed new ATG start codon of the extended BChE protein variant is designated 
No. 1. The known initiation codon of the wt BChE is No. 3. The substitution at nucleotide −32 TGC > TAC 
(c.−32G >A) p.C-11Y (rs1126680) is enlarged and underlined. (B) The peptides of the N-BChE identified by 
mass spectrometry are shown in bold red under the corresponding sequence of the first 60 aa. (C) Influence of 
alteration c.−32G >A (rs1126680) on two putative secondary structures of the first 200 nt of the BCHE mRNA. 
Two models with different energy values were generated for 37 °C using the MFOLD algorithm46 and visualized 
by RnaViz 257. It is hypothesized that c.−32G> A (rs1126680) substitution (shown in black circle) does not 
influence the structure of 5′UTR, but probably lowers the affinity of binding proteins. This allows a hairpin to 
form (comprising Kozak sequence as well as initiation codon AUG No. 3) resulting in changing the initiation 
codon from No. 3 to No. 1, accompanied by a decrease in protein synthesis.
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Discussion
Genetically, the ε4 allele of the apolipoprotein E (APOE) gene is the strongest risk factor for late-onset AD49. 
Several competing hypotheses explain the cause of the disease. An early hypothesis, that AD is defined by the 
presence of Aβ plaques and neurofibrillary tangles became inadequate when it was found that the brains of up to 
40% of cognitively normal older adults also had Aβ plaques and tangles. Additional markers of AD are required 
to facilitate a more accurate diagnosis of the disease. This study shows that the coexistence of the APOE-ε4 allele 
and 3 SNPs in the BCHE gene, localized in 5′UTR (rs1126680) and in intron 2 (rs55781031) of the BCHE-K allele 
(rs1803274), is associated with a highly elevated risk of late-onset AD.
Little is known about regulation of BCHE gene expression. Our previous studies and results presented by 
others have shown that c.−32G> A (rs1126680) (also known as −116A) substitution in exon 1 was associated 
with lower BChE activity45,50. It was shown that 5′ UTR c.−32G> A, (rs1126680) variant is preferentially found 
in cis with K variant (c.1699G> A, p.A567T) and intron 2 alteration (c.1518-121 T > C, rs55781031). It was also 
discussed that c.−32G> A is responsible for lowering of BChE activity by affecting transcription and/or trans-
lation. It was considered that 5′ UTR c.−32G> A, (rs1126680) variant can directly modulate protein translation 
through alterations in mRNA secondary structure. Protein translation is often regulated by mRNA secondary 
structure. Complementary sequences within the 5′ UTR can form stable stem-loop structures that may disturb 
initiation of translation51,52. A theoretical model of the mRNA secondary structure of the BCHE 5′ UTR region 
presented in Fig. 1C was predicted using mFold46. It is possible that the position of substitutions in the loop of 
the stem could affect binding of the regulatory proteins and disturb translation efficiency. Such a process was 
previously described for 5′ UTR of the ferritin receptor mRNA, which contains a stem loop that recruits binding 
proteins and controls translation efficiency53. Here, we observed two effects of c.−32G> A, (rs1126680): change 
in initiation codon of BChE protein resulting in N-extension of the 41 amino acids of the protein and alteration in 
the extended amino acid sequence p.C-11Y. Furthermore, we showed that the N-extension of the BChE protein 
was associated with some cases of late-onset AD. It is noteworthy, that N-terminally extended membrane variants 
of AChE were observed in brain neurons and hematopoietic cells as an effect of alternative splicing54. Extended 
N-AChE proteins may have transmembrane domains at their N terminus and play a role in apoptosis55. Our 
research shows N-terminally extended BChE variant produced as an effect of alternative translation start.
Our results show no association between AD risk in patients carrying the ApoE4 allele and the BChE K-variant 
when no other BCHE gene mutations are evaluated. This conclusion is based on the finding that 6 out of 18 con-
trol cases (33%) and 18/55 AD patients (33%) were positive for the BChE K-variant. However, a strong associa-
tion (100%) was found between late-onset AD in patients carrying the ApoE4 allele and the BChE K-variant when 
2 additional mutations in noncoding regions of the BCHE gene were present.
Different types of dementia may be caused by different molecular mechanisms. Many factors can be involved 
in development of late-onset AD. In this study, we found synergy between APOE-ε4 and SNPs localized in the 
BCHE gene (rs1126680, rs55781031, rs1803274) in 18% of patients with late-onset AD (n = 55). Despite the 
small number of patients, we propose that the presence of the APOE-ε4 allele and 3 SNPs in the BCHE provides 
100% confidence in predicting late-onset AD. These multiple gene alterations were present only in patients with 
late-onset AD. The limitation of our study is that only 18% of late-onset AD patients carried all these mutations. 
A larger cohort study that considers additional genetic and environmental factors may account for the 82% of 
late-onset AD cases that did not contain this set of mutations.
Materials and Methods
AD patients (n = 55) enrolled in the study were selected by specialists in geriatric psychiatry as described earlier56. 
Briefly, the diagnosis of AD was based on medical interviews, clinical symptoms, appropriate imaging examina-
tions and clinical tests including the Hachinski Ischemic Scale, the Geriatric Depression Scale, the Mini Mental 
State Examination (MMSE) and the Clock Drawing Test. In order to exclude other possible causes of impairments 
in cognitive function, complete blood count, a lipidogram and other tests clinically appropriate for somatic dis-
eases were performed during the diagnostic process. The patient group consisted of 26 males and 29 females with 
a mean age of 83 years (range 65–102 years). The control group (n = 18) had no signs or symptoms of dementia or 
a severe somatic disorder. Controls consisted of 9 males and 9 females with a mean age of 76 years (range 68–87 
years). All participants were of European origin and homogeneous ethnic (Polish) background. Serum collection 
and genotyping of the control group (n = 1200) was described earlier45.
No. of ATG 
from 5′ end
Position of 
protein start* Reliability
Identity to Kozak 
rule A/GXXATGG
Sequence (first 
7 aa)
ORF 
Lenght (aa)
1 −123 0.17 tXXATGt MSVQSNL 643
2 −57 0.06 tXXATGa MIFTPCK 621
3 +1 0.14 AXXATGc MHSKVTI 602
Table 2. The ATGpr computer program was used to predict the initiation codons of the BCHE gene58. Two 
additional putative initiation codons (No. 1 and 2) were found in the same open reading frame as the known 
one (No. 3) as shown in Fig. 1. The calculated reliability score of 0.17 shows that initiation codon No. 1 has the 
best match to the Kozak translation initiation site. *-Numbering of positions of the first nucleotide-A in ATG 
of the predicted translation initiation codons in the transcript is described according to position of the first 
nucleotide-A in ATG of the known one (No. 3).
5Scientific RepoRts |          (2019) 9:5223  | https://doi.org/10.1038/s41598-019-41578-3
www.nature.com/scientificreportswww.nature.com/scientificreports/
DNA Extraction, PCR Amplification and Sanger Sequencing. Genomic DNA was extracted from 
1 mL of peripheral blood leukocytes using Blood Mini kit in accordance with the manufacturer’s protocol (A&A 
Biotechnology, Poland). Sequences of 4 amplicons of the BCHE gene were determined using the method pre-
viously described45. Briefly, 4 regions of the BCHE gene were amplified by PCR using the following primers 
M1F, 5′-F- AGACTACCTGCAATTGTAAAGCA, and M1R, 5′-TCTCATCCCACAGAATGAGC; M2-2F, 
5′- GCCACAGTCTCTGACCAAGTG and M2-2R-5′- TTCTGTTCCTAGCTTCATAAAGAG; M3-F, 5′- CACTAA 
GCCCAGTTCACATACG, M3-R, 5′- CATCACCGTGCCTTGGAG; M4-1F, 5′- TGTACTGTGTAGTTAGAG 
AAAATGGC; M4-1R, 5′- TACTAAGTTAAAGATGTGAGGAATC.
APOE- ε2/ε3/ε4 alleles (rs429358, rs7412) polymorphism were determined using the following primers 
APO4F 5′-ACGCGGGCACGGCTGTCCAAGGAG and APO4R 5′-CTCGCGGGCCCCGGCCTGGTACAC. A 
25-μL PCR mixture contained 60 ng of extracted DNA, 10 pmoles of each forward and reverse primer, dNTPs, 
buffer, and Marathon Taq DNA polymerase (A&A Biotechnology, Poland). Amplification was performed with 
an initial denaturation at 95 °C for 5 minutes, followed by 35 cycles of denaturation at 95 °C for 30 s, anneal-
ing at 55 °C for 30 s, and extension at 72 °C for 30 s with a final extension at 72 °C for 10 minutes. PCR prod-
ucts were purified using Clean Up kit (A&A Biotechnology, Poland). Bidirectional DNA sequencing of PCR 
amplification products was performed using BigDye Terminator v.3.1 cycle sequencing kit and 3130 Genetic 
Analyzer according to the manufacturer’s protocol (ThermoFischer Scientific, USA). Sequences were analyzed 
by Sequencher v.4.10 DNA Software (Gene Codes Corporation, USA) and aligned with BCHE APOE reference 
genomic sequences.
Purification of BChE from serum by affinity chromatography on Hupresin® and mass spec-
trometry. Human BChE was purified from 0.1 mL of serum on 50 ul of Hupresin AC Sepharose (Chemforase, 
Mont-Saint-Aignan, France). Hupresin AC was equilibrated with 100 mM NaCl, 20 mM TrisCl pH 7.4 and serum 
proteins were loaded on the 50 µl resin in 1.5 ml filter tubes and washed using 100 mM NaCl, 20 mM TrisCl pH 
7.4 buffer. BChE complexes were eluted with 50 µl of 0.5 M trimethylammonium chloride (TMA Cl) in 100 mM 
NaCl, 20 mM TrisCl pH 7.4 buffer. Eluted proteins were dialyzed and concentrated to 20 µl in Amicon Ultra 10 K 
Centrifugal Filters. Subsequently, eluted proteins were applied to a gel filtration chromatography column, TSK 
gel 3000 SWXL (300 × 7.8 mm, Tosoh) equilibrated with 10 mM phosphate buffer pH 7.4; 8 g/L NaCl at a flow 
rate of 1 ml/min at RT. The column was connected to a Merck Hitachi LaChrom HPLC system equipped with an 
L-7420 UV-Vis detector. Eluted fractions with BChE activity were collected and concentrated to 20 µl in Amicon 
Ultra 10 K Centrifugal Filters. BChE activity of each fraction was determined spectrophotometrically by modified 
Ellman’s method using BTC (S-butyrylthiocholine iodide) as a substrate. The assay was performed in 96-well 
microtiter plates in a final reaction volume of 200 μl of 100 mM PB buffer (pH 7.4) with a final concentration of 
0.5 mM DTNB (5,5′-dithiobis(2-nitrobenzoic acid)) and 5 mM BTC. The absorbance was monitored at 412 nm by 
repeated measurements at 1 min intervals for 10 minutes by a thermostated microplate reader spectrophotometer 
(Tecan Infinite M200Pro) at 25 °C. 50 μL of 100 mM ammonium bicarbonate buffer was added to the each protein 
sample, reduced with 5 mM TCEP for 30 min at 60 °C, blocked with 10 mM MMTS for 15 min at RT and digested 
overnight, shaking with 10 ng/ml trypsin (CAT NO V5280, Promega) at 37 °C. Finally, to stop digestion trifluo-
roacetic acid was added at a final concentration of 0.1%. The digest was centrifuged at 4 °C, 14 000 g for 30 min, to 
pellet solids. The particle-free supernatant was analyzed by LC-MS/MS in the Laboratory of Mass Spectrometry 
(IBB PAS, Warsaw) using a nanoAcquity UPLC system (Waters) coupled to an Orbitrap Elite mass spectrometer 
(Thermo Fisher Scientific). The mass spectrometer was operated in the data-dependent MS2 mode, and data were 
acquired in the m/z range of 300–2000. Peptides were separated by a 180 min linear gradient of 95% solution A 
(0.1% formic acid in water) to 35% solution B (acetonitrile and 0.1% formic acid). The measurement of each sam-
ple was preceded by three washing runs to avoid cross-contamination. The final MS washing run was searched 
for the presence of cross-contamination between samples. Data were searched with the Max-Quant (Version 
1.5.7.4) platform search parameters: match between runs (match time window 0.7 min, alignment time 20 min), 
enzyme: trypsin/p; specific; max missed 2, minimal peptide length 7aa, variable modification: methionine oxi-
dation, N-term acetylation, fixed: cysteine alkylation, main search peptide tolerance 4.5 ppm, protein FDR 0.01. 
Data were searched against home made protein database including isoforms of BChE.
ethical approval and consent to participate. All patients and healthy individuals gave written informed 
consent for molecular genetic testing. The study was approved by the Independent Bioethics Commission for 
Research at the Medical University of Gdansk. The experiments were done in accordance with the Helsinki 
Declaration of 1975.
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